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Der p 1‑based immunotoxin 
as potential tool for the treatment 
of dust mite respiratory allergy
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Immunotoxins appear as promising therapeutic molecules, alternative to allergen‑specific‑
immunotherapy. In this work, we achieved the development of a protein chimera able to promote 
specific cell death on effector cells involved in the allergic reaction. Der p 1 allergen was chosen 
as cell‑targeting domain and the powerful ribotoxin α‑sarcin as the toxic moiety. The resultant 
construction, named proDerp1αS, was produced and purified from the yeast Pichia pastoris. Der p 
1‑protease activity and α‑sarcin ribonucleolytic action were effectively conserved in proDerp1αS. 
Immunotoxin impact was assayed by using effector cells sensitized with house dust mite‑allergic sera. 
Cell degranulation and death, triggered by proDerp1αS, was exclusively observed on Der p 1 sera 
sensitized‑humRBL‑2H3 cells, but not when treated with non‑allergic sera. Most notably, equivalent 
IgE‑binding and degranulation were observed with both proDerp1αS construct and native Der p 1 
when using purified basophils from sensitized patients. However, proDerp1αS did not cause any 
cytotoxic effect on these cells, apparently due to its lack of internalization after their surface IgE‑
binding, showing the complex in vivo panorama governing allergic reactions. In conclusion, herein we 
present proDerp1αS as a proof of concept for a potential and alternative new designs of therapeutic 
tools for allergies. Development of new, and more specific, second‑generation of immunotoxins 
following proDerp1αS, is further discussed.
Allergy or type I hypersensitivity reactions are widely described as a loss of tolerance to certain harmless exog-
enous antigens, such as airborne allergens, foods or insect venoms. Allergies prevalence currently reaches the 
30% among the population in the industrialized countries, experiencing an alarming increment over the last few 
 decades1. Allergies cause a substantial social and economic impact, being the development of new treatments a 
crucial goal for biomedical research. Common symptoms of allergies, such as asthma and rhinitis, share a strong 
T-helper type 2 (Th2) immune polarisation, in combination with a significant decreased activity of the IFNγ-
secreting Th1 cells. Because of this shift, several active mediators are released (e.g. histamine, leukotrienes and 
prostaglandins, among others) by basophils and mast cells, ultimately resulting in the main immune-pathological 
features of the allergic  response2,3.
Despite the well accepted fact that our understanding of the mechanisms underlying allergies has dramati-
cally improved lately, we are still far from developing an effective therapy because of the multifactorial origin of 
this pathology. Accordingly, oral tolerance induction has shown to be highly effective in patients at early ages, 
but it dramatically fails once most immune responses have already been established. Within this same idea, 
allergen-specific-immunotherapy (AIT) arises as a unique  alternative4,5, but carries powerful limitations that 
completely offset its clinical benefits. These limitations include: the variable quality of the vaccine components, 
its unequally effectiveness within patients, the onset of certain adverse side-effects, and its limited action at the 
basis of the Th2-driven effector  phase6,7. Finally, the exact mechanisms underlying the success, or failure, of AIT 
are still under intense debate.
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In this context, immunotoxins arise as a promising approach beyond cancer treatment, revealing themselves 
as promising candidates against inflammatory diseases such as allergies, mainly because of their specific ability 
to promote cell death. Immunotoxins are chimeric molecules that combine a targeting domain-usually anti-
body based-fused to a toxin domain providing the molecule with its cytotoxic  activity8,9. Their mode of action 
comprises three main steps: (1) recognition of the antigen by the targeting domain; (2) cell internalization of 
the complex; and (3) subsequent intracellular release of the active toxic domain which catalytically causes target 
cell  death10,11.
Regarding type I hypersensitivity reactions, the obvious suitable targeting domain for immunotoxin develop-
ment would be the inclusion of an allergen, specifically directed to IgE presented on the cell surface of effector 
(basophils, mast cells) and B  cells12–14. In this sense, an early example of this strategy has been used in animal 
models. Ovalbumin (OVA)-sensitized BALB/c mice were treated with an OVA-diphtheria toxin chimera, which 
resulted in protection from anaphylactic shock after OVA re-challenge15 and simultaneous depletion of OVA-
specific IgE and IgG1 levels but increased  IgG2a16.
In this work we report the development of a different design using the prevalent house dust mite (HDM) 
allergen Der p 1, as targeting domain. Der p 1-sensitization accounts for more than 80% in mite-allergic subjects, 
affecting to more than 20% of the global population and up to 85% of asthmatics allergic to  HDM17. Der p 1 is a 
papain-like cysteine protease which is synthetized as a 34 kDa proenzyme (proDer p 1), consisting of a cysteine 
protease domain (222 residues) and an N-terminal pro-peptide (80 amino acids) that blocks its proteolytic 
 activity18,19. Der p 1 pro-peptide also functions as an intramolecular chaperone ensuring its correct folding and 
extracellular  secretion20. Importantly, this pro-sequence has been used for recombinant Der p 1 production both 
in tobacco plants and in the yeast P. pastoris21–23. Regarding the toxic domain, we have chosen the highly specific 
ribotoxin α-sarcin, an extracellular fungal RNase secreted by Aspergillus giganteus, which specifically cleaves a 
unique single bond of the larger rRNA located at the so-known Sarcin Ricin Loop (SRL)24. This cleavage impairs 
ribosome function and, thereby, causes protein biosynthesis inhibition, leading to programmed cell death by 
 apoptosis25,26. α-Sarcin is the most powerful ribotoxin candidate known so far according to its functional proper-
ties and previously described antitumoral therapeutic  applications27–31.
Herein we present the design and characterization of an innovative allergen-based immunotoxin, consisting 
in the recombinant fusion of the allergen proDer p 1 and α-sarcin, representing a proof of concept for studying 
the potential of these molecules as allergy treatment. The chimeric construct, named proDerp1αS, was produced 
in the yeast P. pastoris and evaluated on humanized basophil-like cells (humRBL-2H3) sensitized with Der p 1 
allergic patients’ sera. Potential non-specific cytotoxicity of the construct was also evaluated in other cell lines 
such as HeLa, Calu-3, LAD2 and Raw 264.7. Finally, the biological relevance of proDerp1αS was reported in terms 
of activation and cytotoxicity against ex vivo basophils from Der p 1 allergic patients and non-allergic individuals.
Results
proDerp1αS generation, production and purification. The corresponding proDer p 1 and α-sarcin 
cDNAs were fused by means of a glycine-glycine-arginine (GGR) linker to produce the proDerp1αS construc-
tion (Fig. 1A and S1). This construction was then cloned in pPICZαA, downstream of the α-factor secretion 
signal sequence within the plasmid, and successfully produced in P. pastoris yeast extracellular culture medium 
(Fig. 1B, C). The protein was purified, after extensive dialysis against 50 mM sodium phosphate buffer, 0.1 M 
NaCl, pH 7.5, by means of a  Ni2+-NTA affinity chromatography, taking advantage of its C-terminal six histidine 
Figure 1.  Domain arrangement of proDerp1αS construct, along with SDS-PAGE, Western blot and mass 
spectrometry analysis of the purified immunotoxin. (A) Schematic representation of proDerp1αS cDNA, 
highlighting its structural and functional motifs, alongside its theoretical molecular mass. 3D-model structure 
of proDerp1αS is included as Figure S1. (B) Coomassie blue stained SDS-PAGE (CBS) and Western blot analysis 
using rabbit anti-α-sarcin (left) and anti-α-Der p 1 antisera (right). CBS protein molecular weight standards 
correspond to Bio-Rad Unstained SDS-PAGE low range Standards; while the prestained Bio-Rad Precision. 
Plus Dual Color Standards (Bio-Rad, Hercules, CA, USA) were used for Western blot. Images correspond to 
full-length gels and blots acquired and analyzed using the Gel Doc XR Imaging System and Quantity One 1-D 
analysis sofware (BioRad) or ChemiDoc-It (UVP) and VisionWorks LS, respectively.Full-length blots/gels are 
presented in Supplementary Figure S2. (C) Mass spectrometry analysis spectrum showing the corresponding 
peak to proDerp1αS construct. The difference between theoretical and empirical masses agrees with the four 
N-terminal extra amino acids of α-factor secretion signal that could remain after its processing by kex2 protease.
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extension (Fig. 1A, in light blue). The purified protein, analyzed by SDS-PAGE, showed a molecular mass in 
agreement with the theoretical 52.6 kDa expected for the chimeric construct (Fig. 1B). The purification yield of 
the protein was 1 mg/L of induction medium.
Structural characterization of proDerp1αS. The purified protein was specifically recognized by both 
anti-α-sarcin and anti-Derp1 rabbit antisera by Western blot immunodetection, proving the chimeric composi-
tion of the construct (Fig. 1B). Furthermore, MALDI-TOF mass spectrometry for proDerp1αS reported a single 
peak which corresponds to the atomic mass expected for the non-processed whole protein plus the four N-ter-
minal amino acids left after kex2 protease processing of α-factor secretion signal (Fig. 1C), indicating thereby 
that Der p 1 pro-peptide was not removed.
Enzymatic characterization. As part of the functional characterization, Der p 1-cysteine protease activity 
of the proDer p 1-based immunotoxin was assayed. The Boc-QAR-AMC fluorogenic peptide assay showed that 
proDerp1αS was an active protease although displaying a slightly lower specific activity than nDer p 1 (Fig. 2A). 
The activity of both proteins (native and chimeric) was indeed specific, being completely abolished by the pres-
ence of the well-known E64 cysteine-protease inhibitor. Regarding the cytotoxic domain, proDerp1αS retained 
the highly specific ribonucleolytic activity of α-sarcin against ribosomes, causing the release of the characteristic 
rRNA α-fragment in a very similar extent to the free fungal wild-type α-sarcin (Fig. 2B).
IgE recognition by HDM allergic human sera. Considering the strategy designed and the mechanism 
of action expected for proDerp1αS on effector cells, the IgE-epitopes binding ability of the allergen within the 
chimera was analyzed. With this purpose, HDM-allergic sera from human patients were assayed for the compar-
atively recognition of proDerp1αS, natural Der p 1 (nDer p 1) and recombinant form of proDer p 1 (rproDerp1) 
in identical conditions (Fig. 3). Allergen-coated indirect enzyme-linked immunosorbent assays (ELISA) using 
individual Der p 1 allergic and non-allergic patients’ sera showed practically identical IgE recognition behavior 
against the three proteins in all cases tested (n = 15), controls included (C1 and C2) (Fig. 3A). Therefore, these 
results showed how the presence of α-sarcin did not impair the ability of specific IgE to recognize the chimeric 
proDerp1αS construct. Regarding inhibition ELISA assays, rproDer p 1 and proDerp1αS showed behaviors that, 
although corresponding to lower inhibition values than nDer p 1, were within the experimental error of these 
assays (Fig. 3B).
Cell toxicity. With the aim of testing the non-specific cytotoxic effect of proDerp1αS, somatic (HeLa and 
Calu-3) and immune (LAD2 and Raw 264.7) representative cell lines were incubated for 24 h with increasing 
tenfold concentrations of α-sarcin or proDerp1αS proteins (Fig. 4). In all cases, the cytotoxic effect of wild-type 
α-sarcin was significantly higher than that of the construct, most especially at the highest protein concentration 
assayed (1 μM) (Fig. 4). In agreement with this observation, the viability of the cultures was almost always over 
90% independently of the proDerp1αS concentration assayed. The exception was Calu-3 cells, that presented 
a remarkable decrease in viability by proDerp1αS—already at 100 nM, but indistinguishable from the fungal 
natural toxin effect (Fig. 4B), suggesting therefore a non-specific origin.
Figure 2.  In vitro functional characterization of the allergen and toxin domains. (A) Comparison between 
nDer p 1 and proDerp1αS cysteine protease activities by mean of Boc-QAR-AMC fluorogenic peptide assay, in 
the absence or presence of E64 cysteine protease inhibitor. (B) Rabbit reticulocytes assays was used for testing 
the ribonucleolytic activity of α-sarcin within proDerp1αS. α-Fragment release, highlighted by a white arrow, 
indicates the specific SRL cleavage. Equimolar amounts (3, 6, 12 pmol) of α-sarcin and immunotoxin were tested 
and compared to ribotoxin-free control, C.
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Serum sensitized humRBL‑2H3 activation and viability inhibition. Degranulation rate of Der p 
1 serum sensitized-humRBL-2H3 cells (n = 6), measured 1 h after stimulation, was similar for rproDerp1 and 
proDerp1αS (Fig. 5, compare results corresponding to serum #1). The β-hexosaminidase release assay mani-
fested an allergen bimodal dose dependent effect, since after showing and increment, degranulation was again 
reduced at the higher protein concentrations employed, basically above 500 nM. HumRBL-2H3 activation was 
exclusively observed when cells were previously sensitized with HDM allergic patient sera. Supporting the speci-
ficity of this effect, α-sarcin never caused degranulation, independently of the serum treatment used (Fig. 5).
The specificity of the cytotoxic effect caused by proDerp1αS on sensitized humRBL-2H3 cells was analyzed in 
parallel experiments using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability 
assays. In this case, the chimeric molecule showed high specific cytotoxicity, promoting cell death exclusively 
on humRBL-2H3 cells sensitized with Der p 1-allergic patients’ sera, but not on those treated with non-aller-
gic patients’ sera (Fig. 5). Comparatively, neither rproDer p 1 nor α-sarcin showed significant cytotoxicity on 
Der p 1-sensitized and non-sensitized humRBL-2H3 cells, thus validating the specificity of the allergen-toxin 
construction.
Human basophils degranulation. The biological relevance of proDerp1αS was studied in terms of 
degranulation using basophils from HDM allergic and non-allergic patients (Fig. 6). Basophil activation test 
(BAT) showed a similar trend in degranulation caused in a dose-dependent manner by nDer p 1, rproDer p 1 
and proDerp1αS in the case of HDM allergic patients (n = 5), with no degranulation caused by α-sarcin in any 
patient analyzed (Fig. 6A). Non-allergic patients (n = 5) did not show any different activation effect respect to 
the controls (data not shown). According to the half maximal effective concentration promoting degranulation 
 (EC50), nDer p 1 (0.00187 ± 0.00267 nM) manifested an activity in the order of tenfold higher than those of 
rproDer p 1 (0.0123 ± 0.0134 nM) and proDerp1αS (0.0151 ± 0.0138 nM) (Fig. 6B). Between rproDer p 1 and 
proDerp1αS  EC50 median values statistically significant differences were not appreciated after the corresponding 
ANOVA analysis (P < 0.186).
Cytotoxic effect on basophils and IgE internalization after proDerp1αS stimulation. After 
showing that proDerp1αS binds to specific-Der p 1 IgEs on basophils surface, with a similar behavior to that 
observed for nDer p 1, its cytotoxic effect on these cells was studied. As it is shown in Fig. 7A, 10 nM proDerp1αS 
treatment did not promote any significant increase in annexin V (apoptotic) or LIVE/DEAD (non-viable) baso-
phil labelling respect to the non-treated cells, neither after 24 h nor after 72 h of incubation. Coherently, identi-
cal results were observed for 0.1 nM concentrations (data not shown). Higher proteins amount, up to 1 μM and 
after 72 h of incubation with either free wild-type α-sarcin or proDerp1αS, caused a significant increase in the 
percentage of apoptotic and non-viable basophils, with independence of patient sensitization subset (Fig. 7B). 
The assays analysing IgE-FcεRI complex internalization after proDerp1αS binding to IgE showed that basophils 
surface IgE levels did not change significantly in the next 4 h after immunotoxin stimulation of Der p 1-sensi-
tized patients’ basophils (#17) (Fig. 7C).
Thereby, according to our results, due to its lack of internalization after surface IgE-binding, proDerp1αS did 
not produced any specific cytotoxic effect on Der p 1-sensitized basophils, regardless of incubation time (24 or 
Figure 3.  Human serum IgE recognition assays. (A) nDer p 1, rproDer p 1 and proDerp1αS comparative 
detection by serum IgE of Der p 1-positive allergic patients (#1–15) and non-allergic (C1, C2) individuals 
by mean of indirect ELISA. Black arrows indicate selected sera for in vitro humRBL-2H3 degranulation and 
viability assays. Asterisks indicate selected patients for BAT and basophils cytotoxicity assays. (B) Inhibition of 
serum binding to nDer p 1 by rproDer p 1 (open circles), the derived immunotoxin chimera (grey circles) and 
using the allergen nDer p 1(black circles) as a control of maximum inhibition. Graph representation shows the 
resulting media ± standard deviation for three sera (#1, 3, 10). All experiments were done by duplicate.
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72 h) or protein concentration (0.1, 10, 1,000 nM) assayed; suggesting a much more complex scenario of primary 
cells instead of the previously described experiments with humRBL-2H3 cell line cultures.
Discussion
Adequate prevention of allergies, diagnosis and treatment are one of the great health challenges of the twenty-first 
century. Due to the variable effectiveness among patients and sometimes adverse secondary effects of  AIT32, new 
therapeutic alternatives and complementary approaches to AIT have been developed in the last  years33. Many 
of them are based on biological treatments, including immunomodulatory strategies such as IgE-blocking anti-
bodies as  Omalizumab34 and those directed to membrane-linked IgEs (mIgE) on memory B  cells35 and against 
FcƐRI receptor on effector  cells36,37.
In this work we present a new alternative approach based on the production, and structural and functional 
characterization of proDerp1αS, an allergen-directed immunotoxin targeted against IgE- and/or FcεRI-positive 
effector cells. This proDerp1αS chimera was produced as a homogeneous soluble polypeptide chain of 53 kDa, 
which integrates the ability to bind FcεRI-positive cells and the cysteine protease activity described for Der p 
1 allergen and the ribonucleolytic catalytic activity of α-sarcin. Although proDer p 1 has been described as an 
inactive zymogen due to the blocking of the active site by its N-terminal pro-peptide, proDerp1αS presented 
proteolytic activity against the Boc-QAR-AMC substrate, albeit minor than nDer p 1 mature protease. An 
explanation to this fact could rely on a structural distortion of N-terminal pro-peptide induced by the α-sarcin 
domain, as in proDer p 1 three-dimensional structure the C-terminal segment of the pro-peptide is located very 
close to proDer p 1 C-terminus, where α-sarcin is fused in the  construct18,38.
As a major rule, the cytotoxic specificity of immunotoxins depends on the proper functionality of its marker 
 domain9. In this case, this function lies on the proDer p 1 domain, which is expected to direct proDerp1αS against 
the allergen-specific effector cells. Therefore, its correct functionality is defined based on its adequate recognition 
Figure 4.  Viability inhibition assays comparing α-sarcin and proDerp1αS cytotoxic activities. The unspecific 
cytotoxic effect on α-sarcin (black boxes) and its derived allergen-based immunotoxin proDerp1αS (grey boxes) 
was evaluated on HeLa (A), Calu-3 (B), LAD2 (C) and Raw 264.7 (D) cells by MTT viability assays. Graph 
represents the means of duplicates and its standard deviation for all the experiments.
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by Der p 1-allergic patients IgEs. Accordingly, all sera from 15 allergic individuals recognized proDerp1αS in a 
very similar way as nDer p 1 or rproDer p 1, being the inhibition ability of the chimera slightly lower than the 
corresponding to nDer p 1. This was expected because of the molecular differences existing between rproDer 
p 1, unprocessed and non-glycosylated in Asn132, and the natural form of Der p1 (nDer p 1) to which allergic 
patients have been naturally  sensitized18,21,38. These results, together with the enzymatic characterization of 
proDerp1αS, suggested an optimal conformational features for the immunotoxin and, more notably, an important 
maintenance of the main IgE-binding regions presented on nDer p 1.
proDerp1αS produced a dose-dependent degranulation on both allergic sera-sensitized humRBL-2H3 cells 
and Der p 1 allergic patient-derived basophils, but not on those humRBL-2H3 cells sensitized with control non-
atopic sera or basophils from non-allergic individuals. These results indicate that proDerp1αS effectively binds 
to the surface receptors of these cells and, it occurs specifically through the IgE-FcεRI complex which cause the 
cross-linking of FcεRI receptors and ultimately the cell  degranulation12.
Simultaneously, it was demonstrated that the cytotoxic effect of proDerp1αS on humRBL-2H3 cells was 
specific and strictly dependent on the presence of Der p 1-specific IgE on their cell surface, inhibiting cell viabil-
ity only in those cells previously sensitized with Der p 1 allergic patients’ serum. In these cases, although the 
concentration to promote a significant decrease in cell viability was high  (IC50 > 0.1 μM), when tested on 1 μM 
proDerp1αS promoted a potent cell viability inhibition, reaching values of 75–80% for all cases tested. These 
experiments reaffirmed the selective toxicity of proDerp1αS, showing no significant effect on the viability of the 
humRBL-2H3 cell cultures sensitized with control non-allergic sera.
Figure 5.  Serum sensitized humRBL-2H3 degranulation and viability inhibition assays. HumRBL-2H3 cells 
sensitized with Der p 1-positive allergic (#1, 5, 6, 12, 13) and non-allergic (C1) individuals’ sera were treated 
with proDerp1αS for degranulation and viability analysis, performed by β-hexosaminidase release (β-Hex. 
% of total) and MTT viability assays, respectively. α-Sarcin and rproDer p 1 were used as controls with a 
representative serum of each allergic and non-allergic groups (serum #1 and C1, respectively). Bars represent 
means of duplicates and its standard deviation for all the experiments. (*) indicates technical limitations by no 
longer availability for serum from this patient.
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Unlike the humRBL-2H3 cells, proDerp1αS did not produce any specific cytotoxic effect on basophils of 
patients allergic to Der p 1. Since the binding of proDerp1αS to these cells was previously proven, the analysis 
of this outcome suggested three possible explanations: (1) the lack of cell internalization of the proDerp1αS-
IgE-FcεRI complex, (2) the degradation of the toxic domain of the construct before its release to the cytoplasm 
and (3) the resistance of basophils to the cytotoxic mechanism of ribotoxins. Since the last two options have 
not been previously demonstrated in any cell  kind9,26, the most feasible justification is the absence of IgE-FcεRI 
internalization in basophils after their allergen-mediated cross-linking in the plasma membrane. As a result, the 
radically divergent behavior of proDerp1αS specific cytotoxicity between humFcεRI RBL-2H3 cells and human 
basophils would be based on differences in the destiny of the cellular IgEs after allergen binding on those cells. 
In this sense, RBL-2H3 cells have been described to suffer a rapid internalization of these allergen-IgE-FcεRI 
 complexes39,40, similar to which takes place in tissue mast  cells41. On the other hand, although human basophils 
have shown to internalize serum IgE through FcεRI in an allergen-independent  way42, this internalization has not 
been demonstrated after allergen binding; which is in line with the current understanding of circulating basophils 
as purely effector  cells43,44. As an approximation to proDerp1αS-IgE-FcεRI complexes behavior in basophils of 
Der p 1 allergic patients, we showed that cell membrane IgE levels remained unchanged for at least 4 h after 
stimulation with the immunotoxin. This result, coupled with the absence of any specific cytotoxic effect during 
the 72 h following stimulation with proDerp1αS, suggests that circulating human basophils do not internalize 
the allergen once it is bound to IgE, holding the whole complex at the surface for longer periods of time, thus 
preventing from the cytotoxic effects coming from proDerp1αS.
Regarding the in vivo potential effect of proDerp1αS, mIgE-Der p 1 + memory B cells—producers of specific 
soluble IgEs—have been proposed as one of the most relevant alternative cellular targets of our strategy, whose 
elimination would provide a greater therapeutic impact on the course of the allergic  disease45. In this case, these 
cells present an efficient internalization of natural allergens after their binding to mIgE (membrane-bound 
IgEs)46,47, providing a promising target for proDerp1αS cytotoxic actions. Furthermore, as bolus administration 
of therapeutic immunotoxins provides a potential systemic range of  action8,9, these kind of molecules would 
allow memory cells depletion with independence of its tissue location.
In conclusion, proDerp1αS reveals itself as a suitable proof of concept example of an allergen-directed immu-
notoxin. Thus, the results presented here are consistent with the potential benefit of using a new type of biologic 
tools capable of provoking specific cell death on those involved in allergic reactions. Although this chimeric 
molecule could be considered as a potent cytotoxic agent against allergy-affecting cells, there is a great need of 
a deep in vivo characterization of its effect during the course and allergic reaction, in order to state categorically 
their therapeutic potential. In short, the existence of a wide set of molecular targets which are potentially suitable 
for the development of more immunotoxins against  allergies48, the increasing relevance of therapeutic antibodies 
in the treatment of allergic  diseases49 and the excellent properties of these molecules in terms of specificity and 
cytotoxic  potency8,9, make immunotoxins a family of biotechnological tools with great potential for the treat-
ment of allergic inflammatory reactions.
Methods
proDerp1αS cloning in pPICZαA and electroporation of BG11 P. pastoris cells. Optimized 
proDer p 1 cDNA sequence for P. pastoris expression was acquired from IDT Technologies (Coralville, IA, USA). 
EcoRI and NotI restriction sites were included in 5′ and 3′ ends. After digestion, proDerp1-specific cDNA was 
cloned downstream of α-factor signal peptide, providing the effective secretion of the protein to the extracel-
lular media after its being processed by kex2 protease, and upstream of α-sarcin sequence in vector pPICZαA. 
Sequence identity was analyzed by sequencing the whole construct including the 3-amino acids linker (Gly-
Gly-Arg) between the two domains. PmeI-linearized pPICZαA/proDerp1αS construct was electroporated in 
Figure 6.  Basophil degranulation. (A) Basophil activation test dose dependant profiles for nDer p 1, rproDer p 
1, proDerp1αS and α-sarcin performed with basophils from Der p 1-allergic patients (n = 5). Individual profiles 
of each patient are presented in Supplementary Figure S3. (B) nDer p 1, rproDer p 1 and proDerp1αS individual 
and medium  EC50 representation for the five Der p 1 allergic patient. Black horizontal gross bars represent the 
 EC50 means while upward deviation bars the sample standard deviation.
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P. pastoris BG11 strain. The resulting electroporation mixture was plated in YPDS-agar containing 100, 400 or 
750 μg/mL of zeocin for selecting purposes.
proDerp1αS expression and purification. proDerp1αS optimal expression was studied in different P. 
pastoris transformants. The two most productive colonies were chosen for the scaling up process. The selected 
colony was grown, from a preculture including zeocin, in 6 × 2 L baffled flasks containing each one 380 mL of 
BMGY (buffered media for yeast containing glycerol) for 24 h at 30 °C and vigorous shaking. The induction was 
done in 5 flasks with 200 mL of BMMY (buffered media for yeast containing methanol) induction medium dur-
ing 48 h at 25 °C. After 24 h 0.5% (v/v) of methanol was added to the media. For its purification the supernatant 
medium was obtained by centrifugation. Then, it was dialyzed in 25 kDa membranes against 50 mM sodium 
phosphate buffer, 0.1 M NaCl, pH 7.5. This medium was loaded in a  Ni2+-NTA chromatography column (His-
TrapTM FF Columns, GE Healthcare, Fairfield, CT, USA). After washing the column with dialysis buffer and the 
same buffer containing 20 mM imidazole, the protein was eluted when adding 250 mM imidazole to the same 
phosphate buffer.
Western blot analysis. After purification proceeding, the samples were examined by 15% (v/v) sodium 
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE). The structural identity of the purified chi-
mera was analyzed in Western blot by both anti-Der p 1 and anti-α-sarcin rabbit polyclonal antisera and then 
detected with a goat anti-rabbit antibody conjugated with horseradish peroxidase (GAR-HRP).
Mass spectrometry analysis. The molecular mass analysis by MS-MALDI TOF was carried out in Prot-
eomics and Genomics Facility (CIB-CSIC), member of ProteoRed-ISCIII network. The experiments were per-
formed on an Autoflex III MALDI-TOF-TOF instrument (Bruker Daltonics, Bremen, Germany) with a smart-
beam laser. Samples were analyzed in the positive ion detection and delayed extraction linear mode. Typically, 
1,000 laser shots were summed into a single mass spectrum. External calibration was performed, using Bovine 
Serum Albumin from Sigma, covering the range from 20,000 to 70,000 kDa. A saturated solution of sinapinic 
acid in 3:1 water/acetonitrile and 0.1% TFA was used as the matrix. The sample solution and the matrix were 
premixed (1:1, v/v) and then 1 µL of the mixture was spotted on the stainless steel target (Bruker-Daltonics) and 
allowed to dry at room temperature.
Cysteine protease activity. Immunotoxin Der p 1 protease activity was studied comparatively to nDer p 
1, through Boc-QAR-AMC (N-tert-butoxycarbonyl-Gln-Ala-Arg-AMC [AMC = 7-amino-4-methylcoumarin]) 
hydrolysis assay, which is widely used for the determination of the proteolysis against a peptide  substrate50. 
Boc-QAR-AMC substrate (75 nM) was incubated with nDer p 1, rproDer p 1 and proDerp1αS (75 nM) in a 
final volume of 200 µL PBS under optimal buffer conditions (5 mM L-Cysteine) within 96-well white polysty-
rene microtiter plates. Peptide hydrolysis was monitored by measuring free AMC fluorescence on a FLUOStar 
Optima fluorometer (BMG LABTECH, Offenburg, Germany) with excitation and emission filters set at 380 nm 
and 480 nm, respectively, at 1 min-intervals for 10 min at 25 °C. Der p 1-free reactions were used as negative con-
trols and background counts obtained were subtracted from each value. E64 (10 nM) cysteine protease inhibitor 
was included as specific activity control. All experiments were performed in duplicate.
Ribonucleolytic activity. The specific ribonucleolytic activity of ribotoxins hydrolyzing SRL is usually 
detected by the release of a 400 nt fragment (α-fragment) from eukaryotic  ribosomes51. Thereby, we studied 
comparatively the ribonucleolytic activity of proDerp1αS against ribosomes contained in a rabbit cell-free retic-
ulocyte lysate, as previously  described52. Briefly, after diluting the reticulocytes extract threefold with 40 mM 
Tris–HCl, pH 7.5, containing 40 mM KCl and 10 mM ethylenediaminetetraacetic acid (EDTA), 50 μL aliquots of 
this dilution were incubated for 15 min at room temperature with different amounts of proDerp1αS and α-sarcin 
as a control. The resulting RNA was analyzed following a phenol/chloroform extraction and isopropanol pre-
cipitation. Finally, after washing and resuspending the resulting pellet with 70% (v/v) − 20 °C ethanol, RNA was 
resuspended in DEPC-H2O. α-Fragment release was visualized by ethidium bromide staining of electrophoresis 
on denaturing 2% agarose gels.
proDerp1αS recognition by human serum IgE. The allergen-specific IgE recognition by human sera of 
nDer p 1, rproDerp1 and proDerp1αS was studied by indirect ELISAs. ELISA microplate wells were coated with 
37 pmol of the different proteins, binding overnight at 4 °C. Then, after blocking with 3% (w/v) non-fat milk-
Figure 7.  proDerp1αS cytotoxic and IgE internalization effect on basophils. Proapoptotic (annexinV-positive 
cells) and viability inhibiting (LIVE/DEAD-positive cells) effect of proDer p 1, α-sarcin and proDerp1αS on 
human basophils from Der p 1 allergic (grey boxes) and non-allergic patients (black boxes). Graphs show the 
results according to the protein concentration stimulus, 10 nM (A) and 1 μM (B), and incubation time, 24 or 
72 h. All results include medium ± standard deviation of values obtained from three Der p 1-allergic patient 
and two non-allergic individuals. (C) Surface anti-IgE labelling on basophils  (CCR3+/CD203c+) contained 
within different blood aliquots from patient #17 (Der p 1-allergic). After 10 min of stimulation at 37 °C with 
proDerp1αS, prior to external IgE labelling, the corresponding aliquots were incubated as follows: 4 h at 4 °C 
as non-internalization control (red), 20 min at 37 °C (blue) or 4 h at 37 °C (green). A non-labelled aliquot was 
included as a blank (grey).
▸
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PBS, the selected sera, diluted tenfold in blocking buffer, were incubated for 2 h at 37 °C. Human serum IgEs 
were detected by using an anti-human IgE rabbit antiserum followed by a goat anti-rabbit antibody labelled with 
horse radish peroxidase (GAR-HRP). Between incubations, wells were washed with 0.1% (v/v) Tween 20-PBS. 
Development was performed by adding 100 μL/well of 0.1 M sodium citrate, pH 5.0, 4% (v/v) methanol, 3.5 mM 
OPD (1,2-phenylenediamine dihydrochloride), 0.16% (v/v)  H2O2 and stopped with 100 μL/well of 10 N  H2SO4. 
Specific IgE recognition was quantified by measuring the optical density at 492 nm.
Additionally, inhibition ELISA were performed for comparing IgE epitope affinity between the natural aller-
gen, its recombinant form and the derived immunotoxin. Following the indirect ELISA protocol, microplate 
wells were coated with nDer p 1 (37 pmol) and incubated with sera inhibited with proDer p 1, proDerp1αS and 
nDer p 1. This inhibition was performed by using blocking buffer for 2 h at 37 °C under vigorous shaking. The 
results were shown as inhibition % according to the inhibitor concentration and relativized to non-inhibited 
sera. All assays included duplicates for each condition.
Cell line cultures. HeLa cells were cultured in DMEM medium supplemented with 10% of fetal bovine 
serum (FBS). Calu-3 bronchial epithelial cell line, derived from lung adenocarcinoma, was cultured in DMEM/
Nutrient Mixture F-12 adding 10% of FBS. Both cell cultures were harvested and propagated routinely by trypsi-
nization. Raw 264.7 cell line, mouse macrophages, was cultured in DMEM with 10% FBS. These cells were prop-
agated by softly scraping. Rat basophilic leukemia cells (RBL-2H3) transfected with cDNA coding for the human 
high affinity IgE receptor chains (humFcεRI) were kindly donated by Dr. Lothar Vogel (humRBL-2H3, Paul-
Ehrlich-Institut, Langen, Germany). These cells were grown in MEM supplemented with 5% (v/v) of FBS and 
propagated twice a week using EDTA 10 mM. Cell cultures were confluent prior to being harvested for use in 
experiments. Moreover, all media contained l-glutamine (300 mg/mL), 50 U/mL of penicillin and 50 mg/mL of 
streptomycin. Culture maintenance was performed at 37 °C in a humidified atmosphere  (CO2:air, 1:19, v:v). The 
human mast cell line  LAD253 was kindly provided by Drs. Dean Metcalfe and Arnold Kirshenbaum (National 
Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA). Serum-free Stem Pro-34 media (Inv-
itrogen, Carlsbad, CA, USA) contains 2 mM l-glutamine, 100 IU/mL penicillin, 100 µg/mL streptomycin and 
100 ng/mL recombinant hSCF (Peprotech, London, UK).
N‑acetyl‑β‑D‑hexosaminidase release. For activation through cross-linking to the IgE receptor, 
humFcεRI expressing RBL-2H3 cells were sensitized overnight with 5% (v/v) of sera from allergic patients. Next 
day cells were stimulated with α-sarcin, rproDer p 1 or proDerp1αS at different concentrations. To increase and 
stabilize the secretion of β-hexosaminidase, 50% (v/v)  D2O was added to the Tyrode’s buffer used for the dilu-
tion of  allergens54. For detection of the granular enzyme β-hexosaminidase, an enzymatic colorimetric assay was 
used as described  previously55. Briefly, 1 h after stimulation of the cells, 30 μl of supernatant was transferred to a 
96-well plate and mixed with 50 μl of substrate solution (3.5 mg/mL p-nitrophenyl-N-acetyl-β-d-glucosaminide 
dissolved in 40 mM citric acid, pH 4.5). In order to calculate the total β-hexosaminidase activity, cells were lysate 
with 100 μl of 0.1% (v/v) Triton X-100 solution and same procedure was done. The mixtures were incubated for 
60 min at 37 °C. After incubation, 100 μl of glycine 400 mM pH 10.7, was added to each well, and the absorbance 
was measured at 405 nm. The percentage of β-hexosaminidase release was calculated as a percentage of the total 
β-hexosaminidase content in the cells.
Cell viability inhibition. The ribosome inactivation exerted by ribotoxins leads to cellular  death23. Hence, 
in vitro MTT viability assays are widely used for studying the effect of immunotoxins on the metabolic activity 
rate of different cell lines. MTT assay for quantifying as culture viability according to the formation of insolu-
ble purple formazan crystals by metabolic active cells by reducing the MTT yellow dye. We used this method 
for analyzing the effect of proDerp1αS on cultures viability with little modifications according to the cell type 
assayed.
HeLa, Calu-3, LAD2 and Raw 264.7 cells viability assays were performed following the general methodol-
ogy described for previous  immunotoxins28. Briefly, cells were seeded into 96-well plates in culture medium for 
24 h. Then, the medium was removed and 200 μl of fresh free-FBS medium containing the assayed proteins was 
added. After 24 h, 100 μl of medium were removed and 20 μl of 5 mg/mL MTT added per well. Finally, after 4 h 
of incubation, the medium was softly removed, and formazan pellets were dissolved in 100 μl of DMSO:methanol 
(1:1). Colorimetric absorbance was measured at 570 nm subtracting 650 nm background. Two different experi-
ments with independent duplicates were carried out.
RBL-2H3 cells expressing humFcεRI were plated at 20,000 cells per well in 96-well plates in 100 μl of medium 
including 5% (v/v) of allergic and non-allergic patients’ sera. The next day, the media were removed and the 
assayed proteins were added at different dilutions in 100 μl of fresh medium. After 24 h, 20 μl of 5 mg/mL MTT 
were added per well and incubated in culture conditions for another 4 h. Finally, the media were removed and 
the colorimetric absorbance was measured as explained before.
Human basophils degranulation. The BAT assays were performed, as previously  described56, includ-
ing samples from D. pteronyssinus allergic patients and non-allergic individuals. First, 100 μl aliquots of fresh 
heparinized whole blood were stimulated for 10 min at 37 °C with 20 μl of stimulation buffer. Then, the assayed 
proteins, diluted in PBS, were added in 100 μl at serial tenfold dilutions from 2.9 × 10–5 nM to 2.9 nM. Polyclonal 
anti-human IgE or PBS alone were used as controls. Cells were stained with anti-hCCR3-fluorescein isothio-
cyanate (FITC), anti-hCD203c-peridinin chlorophyll protein complex (PerCP) and anti-hCD63-phycoeritryn 
(PE) monoclonal antibodies, and erythrocytes were lysed. The stimulation buffer and all the antibodies used in 
this assay were obtained from BioLegend (San Diego, CA, USA). Basophils were gated as  CCR3+ and  CD203c+. 
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Basophil degranulation was determined according to CD63 cell surface expression. All parameters were recorded 
with a FACSCalibur and FACScalibur software (BD Biosciences, San Jose, CA, USA). Data were analyzed with 
FlowJo software (BD Biosciences, San Jose, CA, USA). In all cases, the percentage of CD63-positive basophils 
in the control sample was below 2.5%, setting the cut-off for a positive test to 5%. Basophil allergen threshold 
sensitivity for the different tested proteins was analyzed by dose response curves, using as indicator the lowest 
allergen concentration  (EC50) giving 50% of maximum upregulation of CD63.
Cytotoxic effect on human basophils. Human peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole venous blood from consenting volunteers allergic (n = 3) and non-allergic (n = 2) to HDM. Per 
each individual, 20 mL of blood were gently added over 4 mL of ficoll-paque (Histopaque-1077, Sigma-Aldrich, 
St. Louis, MO, USA) and centrifuged without brake during 30 min at 400 g, R.T. PBMCs fraction was recover 
and washed in a fresh tube with 30 mL of 0.9% (w/v) NaCl and then centrifuged for 10 min, 300 g, R.T. After a 
second wash with 50 mL of the previous solution and another centrifugation in the same conditions, the cells 
were resuspended in 2 mL of PBS containing 1 mM EDTA and 10% (v/v) FBS. Finally, the purified PBMCs from 
each patient were counted, evaluating its viability by mean of trypan blue, and cultured separately in 96-round 
well plates containing 2 × 105 cells/well in 250 μl of RPMI including 10% (v/v) FBS and the assayed stimulus 
(proDerp1αS, rproDer p 1 or wild-type α-sarcin) to a final concentration of 0.1, 10 or 1,000 nM.
Apoptosis and cell viability were evaluated by mean of annexin V-FITC and LIVE/DEAD staining, respec-
tively. Annexin V-FITC is commonly used in flow cytometry to detect apoptotic cells by its ability to bind to 
phosphatidylserine exposed on the outer leaflet of the plasma membrane, a marker of apoptosis. LIVE/DEAD 
kit (Invitrogen) is a viability cell assay used in flow cytometry for simultaneous fluorescence staining of viable 
and dead cell, as it contains calcein-acetoxymethyl and propidium iodide (PI) solutions. In this case non-viable 
cells were assessed by PI staining (LIVE/DEAD+), as it intercalates with the nuclear DNA just in those dead cells 
with areas of disordered cell membrane.
Briefly, after incubating the cultures for 24 or 72 h, culture plates were centrifuged for 5 min at 450 g, resus-
pending the cells in 100 μl/well of annexin V binding buffer (50 mM HEPES, 0.7 M NaCl, 12.5 mM CaCl2, pH 
7.4) containing 1.5 μg/mL of annexin V-FITC or LIVE/DEAD staining diluted 1/1,000.
After incubating 30 min at R.T., the cells were washed with 200 μl of annexin V binding buffer and analyzed 
in a FACScalibur apparatus (BD Biosciences, San Jose, CA, USA). Respectively, basophils were gated as  CCR3+/
CD203c+ within PBMCs lymphocyte/basophil region (FSC/SSC selection) by mean of anti-hCCR3-PE (Bio-
Legend, San Diego, CA, USA) and anti-hCD203c-PerCP antibodies. Single and double staining controls were 
performed for compensating the overlapping fluorescence.
Allergen‑IgE‑FcεRI complex internalization. Using the same general procedure as for the BAT, 100 μL 
of whole blood aliquots were incubated for 10  min at 37  °C after adding 20  μL of stimulation buffer. Then, 
proDerp1αS was added to a final concentration of 10 nM and incubated during 20 min and 4 h at 37 °C or 
directly in ice for non-internalization control. After desired times, the cells were fixed and labelled with anti-
hCCR3-FITC, anti-hCD203C-PerCP and anti-hIgE-PE antibodies (BioLegend, San Diego, CA, USA). Samples 
were tested in a FACScalibur analyzer (BD Biosciences, San Jose, CA, USA), gating on basophils as  CCR3+/
CD203c+, and following anti-hIgE-PE fluorescence indicative of IgE-FcεRI complex internalization.
Patient work‑up. HDM-allergic patients included in this work presented a history of persistent allergic 
rhinitis or/and asthma to D. pteronyssinus, having specific IgE levels to D. pteronyssinus higher than 0.35 kU/L 
(ImmunoCAP-FEIA). Non-allergic subject group was included as a control (specific IgE < 0.35 kU/L). Levels of 
specific IgE to D. pteronyssinus crude extract in sera from allergic patients and non-allergic donors are included 
in Supplementary Table S1.
Sample collection, processing and storing. The biological samples from allergic and non-allergic 
patients were conducted in accordance with the Declaration of Helsinki. The study was approved by the local 
ethics committee (Comité de Ética de la Investigación provincial de Málaga; Servicio Andaluz de Salud, Con-
sejería de Salud Andalucía, España). All participants signed informed consent forms before the study began.
Peripheral blood samples were collected from patients and processed immediately. PBMCs, isolated by Ficoll-
Paque density gradient (Pharmacia Biotech, Barcelona, Spain), and fresh blood aliquots were treated for BAT 
and cytotoxicity assays as described above.
Serum was collected for specific IgE determination, and stored at − 20 °C until further use. Samples were 
managed by the Málaga Hospital-IBIMA Biobank that belongs to the Andalusian Public Health System Biobank.
Specific IgE determination. Levels of specific IgE to D. pteronissynus were determined by ImmunoCAP-
FEIA in serum samples, according to the manufacturer’s instructions (Thermo Fisher Scientific, Massachusetts, 
USA).
Statistical analysis. ANOVA with a post hoc analysis by the Student–Newman–Keuls’ test was used, 
within each test, to compare the results obtained with the different constructions for each concentration in the 
different assays. All values were expressed as arithmetic means ± sem (standard error of the media). Differences 
between experimental groups were considered statistically significant at P < 0.05.
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Equipment and settings. Gel image from Figs. 1B and 2B was acquired and analyzed using the Gel Doc 
XR Imaging System provided with Quantity One 1-D v4.6 analysis software (Bio-Rad, Hercules, CA, USA; www.
bio-rad.com). Blots images from Fig. 1B, were acquired and analyzed using UVP ChemiDoc-ItTS2 provided with 
UPV VisionWorks LS 7.0 analysis software (www.uvp.com). No high-contrast gels or blots has been displayed. 
When processing of brightness and contrast of gel and blot images has been made it was applied to the entire 
image including controls. No cropped gels neither juxtaposing images were displayed.
SigmaPlot-11.0 Scientific Data Analysis and Graphing Software (Systat Software Inc.; www.sigma plot.co.uk) 
was used for statistical analysis and graphing of experimental data in Figs. 1C, 2A, 3, 4, 5, 6 and 7.
Flow cytometry data were analyzed with FlowJo v10.6.2 software (BD.Biosciences, San Jose, CA, USA; www.
flowj o.com).
Data availability
All experimental data generated or analyzed during this study are included in the article.
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